﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Advanced Pharmaceutical Bulletin</JournalTitle>
      <Issn>2228-5881</Issn>
      <Volume>13</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2023</Year>
        <Month>03</Month>
        <DAY>19</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>The Effect of miR-4800 Restoration on Proliferation and Migration of Human Breast Cancer Cells In Vitro</ArticleTitle>
    <FirstPage>378</FirstPage>
    <LastPage>384</LastPage>
    <ELocationID EIdType="doi">10.34172/apb.2023.041</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Monireh</FirstName>
        <LastName>Khordadmehr</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-4472-3847</Identifier>
      </Author>
      <Author>
        <FirstName>Reyhaneh</FirstName>
        <LastName>Matin</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0001-7523-8978</Identifier>
      </Author>
      <Author>
        <FirstName>Behzad</FirstName>
        <LastName>Baradaran</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-8642-6795</Identifier>
      </Author>
      <Author>
        <FirstName>Elham</FirstName>
        <LastName>Baghbani</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-7529-108X</Identifier>
      </Author>
      <Author>
        <FirstName>Farinaz</FirstName>
        <LastName>Jigari-Asl</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0001-5710-970X</Identifier>
      </Author>
      <Author>
        <FirstName>Saeed</FirstName>
        <LastName>Noorolyai</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0001-9686-0854</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/apb.2023.041</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2021</Year>
        <Month>07</Month>
        <Day>20</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2022</Year>
        <Month>01</Month>
        <Day>05</Day>
      </PubDate>
    </History>
    <Abstract>Purpose: MicroRNAs (miRNAs) can contribute to cancer initiation, development, and progression. In this study, the effect of miRNA-4800 restoration on the growth and migration inhibition of human breast cancer (BC) cells was investigated. Methods: For this purpose, transfection of miR-4800 was performed into MDA-MB-231 BC cells using jetPEI. Subsequently, the expression levels of miR-4800 and CXCR4, ROCK1, CD44, and vimentin genes were measured using quantitative real-time polymerase chain reaction (q-RT-PCR) and specific primers. Also, the proliferation inhibition and apoptosis induction of cancer cells were evaluated by MTT and flow cytometry (Annexin V-PI method) techniques, respectively. Additionally, cancer cell migration after miR-4800 transfection was assessed by wound-healing (scratch) assay. Results: The restoration of miR-4800 in MDA-MB-231 cells resulted in the decreased expression level of CXCR4 (P ˂ 0.01), ROCK1 (P ˂ 0.0001), CD44 (P ˂ 0.0001), and vimentin (P ˂ 0.0001) genes. Also, MTT results showed restoration of miR-4800 could significantly reduce cell viability rate (P ˂ 0.0001) compared with the control group. Cell migration remarkably inhibited (P ˂ 0.001) upon miR-4800 transfection in treated BC cells. Flow cytometry data demonstrated that miR-4800 replacement considerably induced apoptosis in cancer cells (P ˂ 0.001) compared with control cells. Conclusion: Taken together, it seems that miR-4800 can act as a tumor suppressor miRNA in BC and play an essential role in modulating apoptosis, migration, and metastasis in BC. Therefore, it may be suggested as a potential therapeutic target in treating BC by performing additional tests in the future.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">microRNA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Malignancy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Replacement</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Therapeutic target</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>